Disease · MONDO_0005015
Comparisons in its trials57
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 57
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Exubera® vs Non-Exubera®: All-cause Mortality: Number of Deaths | 12 of 987 | 9 of 989 | 1,976 | NCT00359801 | Trial comparisons |
| Exubera® vs Non-Exubera®: serious adverse events | 124 of 987 | 109 of 989 | 1,976 | NCT00359801 | Trial comparisons |
| Technosphere® Insulin vs Usual Care: FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care | 42 of 730 | 27 of 824 | 1,554 | NCT00308737 | Trial comparisons |
| Atorvastatin Administration Group vs Rosuvastatin Administration Group: serious adverse events | 14 of 506 | 19 of 516 | 1,022 | NCT01544309 | Trial comparisons |
| MYL-1701P vs Eylea: Number of Participants With Treatment Emergent Adverse Events | 138 of 178 | 138 of 176 | 354 | NCT03610646 | Trial comparisons |
| MYL-1701P vs Eylea: deaths from any cause | 2 of 178 | 4 of 176 | 354 | NCT03610646 | Trial comparisons |
| MYL-1701P vs Eylea: serious adverse events | 31 of 178 | 23 of 176 | 354 | NCT03610646 | Trial comparisons |
| MYL-1701P vs Eylea: Number of Subjects With Induced and Boosted Anti-Drug Antibodies | 5 of 177 | 10 of 176 | 353 | NCT03610646 | Trial comparisons |
| MYL-1701P vs Eylea: Number of Subjects Who Gained ≥15 Letters From Baseline in BCVA | 57 of 176 | 51 of 174 | 350 | NCT03610646 | Trial comparisons |
| Inhaled Insulin vs Subcutaneous Insulin: serious adverse events | 21 of 146 | 13 of 141 | 287 | NCT00139659 | Trial comparisons |
Ezetimibe/Simvastatin vs Doubling Atorvastatin Dose: In Participants Treated With Atorvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of < 70 mg/dL (1.81 mmol/L) | 87 of 156 | 24 of 81 | 237 | NCT00862251 | Trial comparisons |
Ezetimibe/Simvastatin vs Doubling Simvastatin Dose: In Participants Treated With Simvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of < 70 mg/dL (1.81 mmol/L) | 84 of 158 | 19 of 78 | 236 | NCT00862251 | Trial comparisons |
| Active vs Placebo: serious adverse events | 5 of 102 | 6 of 104 | 206 | NCT00486291 | Trial comparisons |
| On-metformin vs Off-metformin: Incidence of Lactic Acidosis | 0 of 83 | 0 of 79 | 162 | NCT01873859 | Trial comparisons |
| On-metformin vs Off-metformin: serious adverse events | 0 of 83 | 0 of 79 | 162 | NCT01873859 | Trial comparisons |
| Glucagon Nasal Powder vs Glucagon Hydrochloride Solution: deaths from any cause | 0 of 71 | 0 of 70 | 141 | NCT03421379 | Trial comparisons |
| Glucagon Nasal Powder vs Glucagon Hydrochloride Solution: serious adverse events | 0 of 71 | 1 of 70 | 141 | NCT03421379 | Trial comparisons |
| Flexible Dose vs Fixed Dose: Hypoglycemia | 24 of 62 | 14 of 59 | 121 | NCT01101867 | Trial comparisons |
| Flexible Dose vs Fixed Dose: serious adverse events | 0 of 62 | 0 of 59 | 121 | NCT01101867 | Trial comparisons |
| Intensive vs Control: Severe Hypoglycemia | 7 of 44 | 2 of 49 | 93 | NCT00609986 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005015/comparisons